Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 8369 - 8376 of 12093 results

Registration for the 2016 Mintz/ML Strategies Pharmacy Industry Summit is Open! (May 10, 2016)
April 12, 2016| Blog| Viewpoint

Ex-NFL Linebacker Files Suit Over 'Lights Out' Pajamas
April 12, 2016| News

Hold on to Your (Fiduciary) Hats: the Countdown to Compliance with the Department of Labor’s Final Fiduciary Rules Begins
April 11, 2016| Blog| Viewpoint

LSU Hospital Operator May Proceed with Antitrust Suit Against Competing Health System
April 11, 2016| Blog| Viewpoint

Talking about The Challenge of Quality in Health Care Policy Development
April 11, 2016| Blog| Viewpoint

Health Fraud Defense Attys Riding High As Wins Pile Up
April 11, 2016| News

"Multi-Agency Interactive Tool" Available for Developers of Health Apps
April 8, 2016| Blog| Viewpoint

Understanding the Extraterritorial Scope of Title VII and the ADA for U.S. Employers
April 8, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
